Helen Susan Kim

CIK: 0001422772

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

AKTS

Aktis Oncology, Inc.

Director10% Owner

PRTA

PROTHENA CORP PUBLIC LTD CO

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Conversion(C)
Indirect
4.9M shares-
AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Purchase(P)
Indirect
812.5K shares at avg. $18.00$14.6M
AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Conversion(C)
Indirect
134.8K shares-
AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Purchase(P)
Indirect
22.5K shares at avg. $18.00$406K
PRTA
PROTHENA CORP PUBLIC LTD CO
May 14, 2025
Award(A)
Stock Option (Right to Buy)
Direct
20.2K shares-

		Type	Shares	Price		Ownership
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Conversion(C)	4,859,370	-	$0	Indirect
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Purchase(P)	812,455	$18.00	$14,624,190	Indirect
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Conversion(C)	134,842	-	$0	Indirect
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Purchase(P)	22,545	$18.00	$405,810	Indirect
May 14, 2025	PRTA PROTHENA CORP PUBLIC LTD CO	Award(A) Stock Option (Right to Buy)	20,183	-	-	Direct

1-5 of 5 transactions

About Kim Helen Susan

Kim Helen Susan (SEC CIK 0001422772) files insider reports with the SEC as Director of Aktis Oncology, Inc. (AKTS) and Director of PROTHENA CORP PUBLIC LTD CO (PRTA).

Signal8 holds 3 ownership filings by Kim Helen Susan (1 Form 3, 2 Form 4), filed between May 16, 2025 and Jan 12, 2026. Those filings report 5 transactions, from May 14, 2025 to Jan 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Kim Helen Susan's filings is in BOSTON, MA.

Recent filings by Kim Helen Susan

Jan 12, 2026: Conversion of AKTS shares (Form 4, code C).
Jan 12, 2026: Open-market purchase of AKTS shares (Form 4, code P).
Jan 12, 2026: Conversion of AKTS shares (Form 4, code C).
Jan 12, 2026: Open-market purchase of AKTS shares (Form 4, code P).
May 14, 2025: Grant or award of PRTA derivative securities (Form 4, code A).

Other insiders filing for Aktis Oncology, Inc. (AKTS)

Czibere Akos, Chief Medical Officer
Herrmann Ken, Director
Ron-Bigger Shulamit, Chief Operating Officer
Gormley Glenn, Director
ELI LILLY & Co, 10% Owner
Foley Todd, Director

How to read Form 4 transaction codes